Professor Richard Scolyer, a world-renowned melanoma pathologist and former Australian of the Year, died at age 59 [1].
Scolyer's death marks the loss of a pioneering scientist who spent his final months serving as a patient in the very experimental therapy he helped create. His willingness to test his own theories on an aggressive form of brain cancer provides critical data for future oncology research.
Scolyer was born in Launceston, Tasmania, in December 1966 [5]. Based in Melbourne, he earned international recognition for his work in melanoma and cancer pathology. In 2024, he was named Australian of the Year [4].
His health declined after he was diagnosed with an aggressive IDH-wild-type glioblastoma in 2023 at age 56 [2, 3]. Rather than pursuing standard care alone, Scolyer volunteered as the first patient for a pioneering experimental treatment he co-designed [1, 2].
Despite the innovative nature of the therapy, the disease proved too aggressive. He died on a Sunday night in early June 2024 [2].
Throughout his career, Scolyer focused on the intersection of immunology and cancer. His final days were spent documenting the effects of the experimental treatment on his own body to aid the scientific community. In a final message, he said to "pursue your dreams and passion with humility, love, and compassion" [1].
“Pursue your dreams and passion with humility, love, and compassion.”
Scolyer's decision to act as 'Patient Zero' for his own experimental therapy reflects a rare convergence of clinical research and personal sacrifice. While the treatment did not save his life, the data gathered from his case may accelerate the development of targeted therapies for glioblastoma, one of the most lethal forms of brain cancer.
